Future of Sciclone Pharmaceuticals | Quantumrun

Future of Sciclone Pharmaceuticals

SciClone Pharmaceuticals, located in Foster City, California, is a pharmaceutical based company. Their product line revolves around major therapeutic markets, such as oncology, infectious diseases, and cardiovascular disorders. One example of their products includes ZADAXIN, SciClone's lead product, which can be used for treating HBV (hepatitis B), HCV (hepatitis C), certain cancers, and can also be used as an immune system enhancer. This company has a substantial commercial business and markets, including multiple branded products in China. SciClone also trades on the NASDAQ Global Select Market using the symbol, SCLN.

Home Country: 
United States
Industry: 
Pharmaceutical
Industry vulnerability to disruption: 

<p>Belonging to the pharmaceuticals sector means this company will be affected directly and indirectly by a number of disruptive opportunities and challenges over the coming decades. While described in detail within Quantumrun’s special reports, these disruptive trends can be summarized along the following broad points:</p>

<p>*First off, the late 2020s will see the Silent and Boomer generations enter deep into their senior years. Representing nearly 30-40 per cent of the global population, this combined demographic will represent a significant strain on the health systems of developed nations.<br />
*However, as an engaged and wealthy voting block, this demographic will actively vote for increased public spending on health services to support them in their greying years.<br />
*The economic strain of this massive senior citizen demographic will encourage developed nations to fast-track the testing and approval process for new drugs that may improve the overall physical and mental health of seniors, so that they remain well enough to lead independent lives outside the care of hospitals and nursing homes.<br />
*By the early 2030s, a range of treatments will emerge to stunt and later reverse the effects of aging. These treatments will be provided annually and over time will become affordable to the masses, resulting in longer average human lifespans and a new windfall for the pharmaceutical industry.<br />
*By 2050, the world population will rise above nine billion, over 80 percent of whom will live in cities. The high numbers and density of the future human population will result in more regular pandemic outbreaks that spread faster and are harder to cure.<br />
*The eventual widespread adoption of artificial intelligence (AI) and quantum computing within the pharmaceutical industry will lead to new, AI-assisted discoveries of drugs and treatments to cure a range of medical conditions. These AI pharmaceutical researchers will also result in new drugs and treatments being discovered at a far faster rate than is currently possible.</p>

Total patents held: 
21
Ranking List: 
491
Ranking List: 
2017 Quantumrun Global 1000
323
Ranking List: 
2017 Quantumrun US 500
53
Ranking List: 
2017 Quantumrun Silicon Valley 100
Market Revenue Country: 
Market country 
China
Revenue from country 
0.95
Prod/Serv name revenue: 
Prod/Serv name: 
Product sales
Prod/Serv revenue: 
155937000
Prod/Serv name: 
Promotion services
Prod/Serv revenue: 
4159000
Founded: 
1989
Company Name: 
Sciclone Pharmaceuticals
Revenue: 
160096000
3y average revenue: 
150714333
Operating expenses: 
126861000
3y average expenses: 
121004333
Company profile data note: 
All company data collected from its 2016 annual report and other public sources. The accuracy of this data and the conclusions derived from them depend on this publicly accessible data. If a data point listed above is discovered to be inaccurate, Quantumrun will make the necessary corrections to this live page.
Global employee count: 
570
Domestic employee count: 
20
Number of domestic locations: 
1
Funds in reserve: 
134395000
Investment into R&D: 
15078000
#491 | 2017 Quantumrun Global 1000
#323 | 2017 Quantumrun US 500
#53 | 2017 Quantumrun Silicon Valley 100

SciClone Pharmaceuticals, located in Foster City, California, is a pharmaceutical based company. Their product line revolves around major therapeutic markets, such as oncology, infectious diseases, and cardiovascular disorders. One example of their products includes ZADAXIN, SciClone's lead product, which can be used for treating HBV (hepatitis B), HCV (hepatitis C), certain cancers, and can also be used as an immune system enhancer. This company has a substantial commercial business and markets, including multiple branded products in China. SciClone also trades on the NASDAQ Global Select Market using the symbol, SCLN.

Home country:
United States
Sector:
Pharmaceuticals
Industry:
Pharmaceutical
Founded:
1989
Global employee count:
570
Domestic employee count:
20

Financial Health

Revenue
$160,096,000 USD
3y average revenue
$150,714,333 USD
Operating expenses
$126,861,000 USD
3y average expenses
$121,004,333 USD
Funds in reserve
$134,395,000 USD
#1 Market country
China
% of revenue from country #1
0.95%

Asset Performance

#1 Product/Service/Dept. name
Product sales
#1 Product/Service revenue
$155,937,000 USD
#2 Product/Service/Dept. name
Promotion services
#2 Product/Service revenue
$4,159,000 USD

Innovation assets and Pipeline

Investment into R&D
$15,078,000 USD
Total patents held
21
All company data collected from its 2016 annual report and other public sources. The accuracy of this data and the conclusions derived from them depend on this publicly accessible data. If a data point listed above is discovered to be inaccurate, Quantumrun will make the necessary corrections to this live page.

Disruption Vulnerability

Belonging to the pharmaceuticals sector means this company will be affected directly and indirectly by a number of disruptive opportunities and challenges over the coming decades. While described in detail within Quantumrun’s special reports, these disruptive trends can be summarized along the following broad points:

*First off, the late 2020s will see the Silent and Boomer generations enter deep into their senior years. Representing nearly 30-40 per cent of the global population, this combined demographic will represent a significant strain on the health systems of developed nations.

*However, as an engaged and wealthy voting block, this demographic will actively vote for increased public spending on health services to support them in their greying years.

*The economic strain of this massive senior citizen demographic will encourage developed nations to fast-track the testing and approval process for new drugs that may improve the overall physical and mental health of seniors, so that they remain well enough to lead independent lives outside the care of hospitals and nursing homes.

*By the early 2030s, a range of treatments will emerge to stunt and later reverse the effects of aging. These treatments will be provided annually and over time will become affordable to the masses, resulting in longer average human lifespans and a new windfall for the pharmaceutical industry.

*By 2050, the world population will rise above nine billion, over 80 percent of whom will live in cities. The high numbers and density of the future human population will result in more regular pandemic outbreaks that spread faster and are harder to cure.

*The eventual widespread adoption of artificial intelligence (AI) and quantum computing within the pharmaceutical industry will lead to new, AI-assisted discoveries of drugs and treatments to cure a range of medical conditions. These AI pharmaceutical researchers will also result in new drugs and treatments being discovered at a far faster rate than is currently possible.